For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

EAY131: Molecular Analysis for Therapy Choice (MATCH)

Clinical Trial Details

NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial.The trial seeks to determine whether treating cancer based on specific genetic changes is effective, regardless of cancer type.

The study drugs included in this trial include single agents and combinations that have at least a recommended phase 2 dose. Potential patients will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered participation on MATCH. 

All participants in the screening study are required to have had a sample of their tumor tested by a MATCH-designated laboratory. If your doctor was informed by this laboratory that you may be able to participate in this study and you agree to take part in the study, the results and some of your health information will be sent by the MATCH-designated laboratory to central reviewers to be used to determine if you are eligible for a MATCH substudy treatment. 

If your tumor has a genetic change or mutation that is targeted by one or more of the drugs used in this study, you will be asked to participate in that substudy. If you are asked to take part in a substudy, a sample of your tumor will be sent to a central laboratory that is being used by the MATCH study. If you decide to take part in the study, you are agreeing to have this tumor tissue submitted to ECOG-ACRIN either by the designated laboratory that previously tested the sample or by your doctor. This sample will be taken from a biopsy of the tumor that was performed before. No additional procedures will be done to obtain tumor tissue just for this study. 

Key Eligibility: 
  • Patients age 18 or older 
  • Not pregnant or breast feeding 
  • Histologically documented solid tumor or confirmed diagnosis of lymphoma or multiple myeloma requiring therapy 


  • Patient has progressed following at least one line of standard systemic therapy and there is not another approved/standard therapy available that has been shown to prolong overall survival. 


  • Patient's disease does not have a standard treatment known to prolong overall survival 

More detailed eligibility criteria when you contact the study team. 

Study contact by location

Upper East Side - Manhattan


June Greenberg, RN
(212) 746-2651

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment